



Innovative pharmacological depression treatment

Hans-Jürgen Möller¹ · Rainer Rupprecht² · Andreas Reif³

Published online: 31 July 2025
© The Author(s) 2025

Treatment of depression with the currently available medications and other neurobiological options is by far not as efficacious as it should be and especially the treatment resistant depression (TRD) needs improved solutions. A recent systematic review and network meta-analysis by Saelens [1] showed very clearly that only six treatments are superior to the other 19, however most of them, apart from ECT, only with a slight advantage. These and other related publications with similar general results demonstrate, that the current common ground of treatment of depression needs urgently innovation and enrichment with new compounds and new mechanisms.

Fortunately the pipeline of new mechanisms and compounds is since the last decade richer than many people in the field might believe. Of course not all new approaches will reach a license or - to expect even more- will be game changers, but at least some of the new developments like especially ketamine/esketamine have already shown their beneficial potential. From there the way to other new developments concerning the glutamatergic pathway might proceed further. But also other mechanisms apart from the currently so potent glutamatergic ones seem promising. Altogether the creativity is remarkable and opens windows in different attractive directions.

In the center of the glutaminergic antidepressants is esketamine, the left turning enantiomer of the racemate ketamine, with its interesting intranasal application mode (FDA

license 2019). Especially the ultrarapid efficacy and the efficiency in TRD makes this compound attractive. Together with the racemate ketamine, which, although widely used, however has no license for the treatment of depression. The two compounds form the core group of the so called rapid acting antidepressants (RAADs). The intensified neurobiological research activities on these compounds in the recent years [2, 3] helped to understand the underlying mechanism much better and to understand that beyond the antagonistic activity at the glutamatergic NMDA receptor also other neurobiological pathways contribute to the efficacy and rapid onset of action.

Other glutamatergic compounds are also in focus of preclinical or clinical research: Ampakanine (positive allosteric modulators of the AMPA-receptors), antagonists on the metabotropic glutamate receptors, the NMDA receptor-antagonist dextromethorphan (in combination with bupropion licensed 2022 by the FDA), nitrous oxide as non-competitive antagonist at the NMDA-receptor [4] etc.

Other mechanism beyond the glutamatergic system are also of interest, like neurosteroids with positive allosteric GABA-A-modulating effects, e.g. zuranolone (2023 licensed by the FDA in the indication post partum depression) and brexanolone [5]. From the group of opioidergic compounds partial agonists of the μ -opioid-receptor and antagonists at the kappa-opioid receptor (z.B. Navacaprant, Aticaprant) are under investigation [6]. TRPC 4/5 inhibitors lead to anxiolytic and antidepressant effects in mice and show promising results in humans [7]. Orexin receptor antagonists are licensed to treat patients who suffer from insomnia, but they might be also of interest to treat depression.

There is a long tradition of phyto-psychopharmaka. The developments in this field are often not seen as so spectacular as in the other fields of psychopharmacology, because their development is mostly in the hands of smaller family companies. But undoubtedly they are of importance under clinical aspects. Silexan, a lavender extract, showing good results in patients with anxiety disorders, is currently evaluated in depression [8].

✉ Hans-Jürgen Möller
hans-juergen.moeller@med.uni-muenchen.de

¹ Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstr. 7, 80336 Munich, Germany

² Department of Psychiatry and Psychotherapy, University Hospital, University Regensburg, Universitätsstr.84, 93053 Regensburg, Germany

³ Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, University Frankfurt, Heinrich- Hoffmann-Str. 10, 60528 Frankfurt am Main, Germany

Since some years there is a hype for psychedelica in the treatment of depression, powerfully supported by the mass media. Psylocybin (a 5HT-2 A receptor partial -antagonist) seems in the center of this development. The very few adequate studies seem to support the hypothesis, that even a very short treatment with psylocybin is efficacious to treat depression. Up to now a license for the treatment of depression is missing. Further candidates of this group are DMT, 5-MeO-DMT, LSD.

A great hope is that pharmacogenetic research will help to improve the prediction of response /remission and, going beyond this, to predict the optimal medication for the individual patient (precision medicine). However so far the respective genetic results are not sufficiently satisfying [9]) It might be still necessary to include other neurobiological like e.g. immunological markers [10] or G protein rafts.

This volume brings a selection a papers which demonstrates the vibrant spectrum of research activities in this field. The space of this volume is too restricted to bring all interesting developments, but the selected papers give a hint into important approaches, which might be of future relevance.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest H.J.Möller is co- editor of EAPC.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted

use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Saelens J, Gramser A, Watzal V et al (2024) Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled studies. *Neuropsychopharmacology*. <https://doi.org/10.1038/s41386-024-02044-5>
2. Johnston JN, Zarate CA, Kivimäki MD (2024) Esketamine in depression: putative biomarkers from clinical research. *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01865-1>
3. Kavalali ET, Monteggia LM (2024) Synaptic basis of rapid antidepressant action. *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01898-6>
4. Kronenberg G, Schoretsanis G, Seifritz E et al (2024) The Boon and Bane of nitrous oxide. *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01801-3>
5. Riebel M, Brunner LM, Nothdurfter C et al (2024) Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression. *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01843-7>
6. Demyttenaere K (2024) Aticaprant, a kappa opioid receptor antagonist, and the recovered interest and pleasure in the concept of major depressive disorder. *Eur Arch Psychiatry Clin Neurosci*. <https://share.google/wCuwPAQOtNnIkHIDZ>
7. Grimm S, Just S, Fuertig R et al (2024) TRPC4/5 inhibitors: phase I results and proof of concept studies. *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01890-0>
8. Kasper S, Eckert A (2024) Silexan in anxiety, depression, and related disorders: Pharmacological background and clinical data. *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01923-8>
9. Martone A, Possidente C, Fanelli G et al (2024) Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets? *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01873-1>
10. Moulton CD, Malys M, Hopkins CWP et al (2024) Activation of the interleukin-23/Th17 axis in major depression: a systematic review and meta-analysis. *Eur Arch Psychiatry Clin Neurosci*. <https://doi.org/10.1007/s00406-024-01864-2>